Now is the Future

Rep. Lauren Boebert might be subject to a mandatory recount in an unexpectedly close campaign in a conservative Colorado district, where she leads her Democratic

The 2022 World Cup is quickly approaching, therefore it’s time to rank some kits (uniforms). Each country that qualifies selects its own kit manufacturer. Nine

Bali is undeniably one of the most dazzling Indonesian islands, and if you have decided to visit this amazing island you are in for a

In his return to the same Los Angeles theater where his historic Oscar smackdown occurred, comedian Chris Rock remarked about how painful it was, referencing

The wrong-way SUV driver accused of purposely striking dozens of Los Angeles sheriff’s recruits on Wednesday, putting some of them in severe condition, was captured,

On a Pennsylvania roadway, a huge piece of debris became wedged underneath a Tesla, which then caught fire. WTAJ reports that a family traveling to

Last month, Tom Brady and Gisele Bündchen finalized their divorce and divided an estimated $770 million in assets, leaving the future of the charity founded

Mr Chair, thank you. This week, our valiant Ukrainian allies dealt President Putin’s misguided adventurism a serious setback. The announcement of Russia’s retreat from Kherson

NASA’s Space Launch System — the space agency’s most powerful rocket yet — launched on its maiden voyage this morning, with significant contributions from Alabama-based

Horizon scanning at the MHRA results in the acquisition of external financing, enabling our scientists to engage in a new area of standardization that will assist the developers and producers of AAV gene treatments. The Issue Gene therapies are drugs that modify an individual’s genes in order to prevent, treat, or cure disease.  These novel techniques belong to the category of medications known as Advanced Therapy Medicinal Products or ATMPs (other ATMP are cell therapies).  A gene therapy drug consists of a carrier or vector that facilitates the transfer of genetic material or genes into cells.  Gene treatments based on Adeno-associated viral (AAV) vectors, which are non-replicating, non-pathogenic, single-stranded DNA parvoviruses, are currently a field of innovation and expansion.  Nonetheless, this field may face analytical and manufacturing obstacles. Analytical methods to assess the presence of impurities, quality, and concentration of a product have been developed, but they are performed without a common point of reference, and different analytic techniques measure different characteristics of the product, limiting comparisons between products, batches, and sites of manufacture.  Standardization of AAV products would enable manufacturers to harmonise dosing and the quality of their goods, thereby boosting patient confidence in these therapies and enhancing the safety of these potentially life-changing revolutionary drugs. The necessary modification Horizon scanning in this instance revealed a need for standardisation of AAV products to support developers and manufacturers of these therapies, to enable patients to access these novel products, and to guarantee they are suitably regulated and safe and effective.  Without a benchmarking material, it is difficult to establish the concentration (copies or particles per mL) and empty/full particle ratio of their products.  To this goal, accessible and universally applicable AAV reference resources are required to improve the field. What the MHRA did To assist with this matter, we combed the